Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial

被引：0
|
作者：
Shi, Qiyun
Qi, Xiaowei
Tang, Peng
Fan, Linjun
Chen, Li
Wang, Shushu
Zhang, Guozhi
Wang, Mengyuan
Che, Hongying
Lv, Pengwei
Chen, Dejie
Hu, Jinhui
Li, Qiuyun
Zhang, Yanwu
Yu, Qiao
Yang, Kunxian
Zhong, Yuan
Chen, Chuang
Zhou, Zemin
Qian, Liyuan
Zhang, Jingwei
Ma, Mingde
Sun, Yi
Liu, Jiangbo
Zhang, Yi
Jiang, Jun
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT2-22-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-22-01
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study
    Yin, Wenjin
    Wang, Yaohui
    Wu, Ziping
    Ye, Yumei
    Zhou, Liheng
    Xu, Shuguang
    Lin, Yanping
    Du, Yueyao
    Yan, Tingting
    Yang, Fan
    Zhang, Jie
    Liu, Qiang
    Lu, Jinsong
    CLINICAL CANCER RESEARCH, 2022, 28 (17) : 3677 - 3685
  • [32] The efficacy and safety of using pyrotinib combined with capecitabine as neoadjuvant therapy in elderly patients with HER2-positive breast cancer: a single-arm prospective clinical trial
    Wang, Wei
    Zhang, Juan
    Chang, Jin-Yi
    Yao, De-Shun
    Hu, Fen
    Liang, Yong -Ping
    Shen, Yan
    Liu, Yu-Qi
    Qi, Huai-Hua
    Tong, Jian-Bin
    Cai, Hai-Feng
    GLAND SURGERY, 2023, 12 (02) : 208 - 214
  • [33] A phase II trial of neoadjuvant epirubicin/cyclophosphamide followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer
    Kodera, A.
    Hirano, A.
    Inoue, H.
    Ogura, K.
    Hattori, A.
    Sakaguchi, S.
    Yukawa, H.
    Matsuoka, A.
    Tanaka, N.
    Kamimura, M.
    Jibiki, N.
    Fujibayasi, M.
    Naritaka, Y.
    Shimizu, T.
    CANCER RESEARCH, 2017, 77
  • [34] Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.
    Yan, Min
    Ouyang, Quchang
    Sun, Tao
    Niu, Limin
    Yang, Jin
    Li, Li
    Song, Yuhua
    Hao, Chunfang
    Chen, Zhanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab and bevacizumab as neoadjuvant therapy for HER2-positive locally advanced breast cancer (LABC) or as adjuvant therapy for HER2-positive pathologic stage III breast cancer (PS3BC): A phase II trial of the NSABP Foundation Research Group
    Smith, J. W.
    Buyse, M.
    Rastogi, P.
    Geyer, C., Jr.
    Jacobs, S.
    Patocskai, E.
    Wolmark, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis
    Mao, Xiaoyun
    Lv, Pengwei
    Gong, Yiping
    Wu, Xiujuan
    Tang, Peng
    Wang, Shushu
    Zhang, Dianlong
    You, Wei
    Wang, Ouchen
    Zhou, Jun
    Li, Jingruo
    Jin, Feng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [37] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
    Liu, Lu
    Zhu, Mingzhi
    Wang, Yanyan
    Li, Muhan
    Gu, Yuanting
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [38] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
    Lu Liu
    Mingzhi Zhu
    Yanyan Wang
    Muhan Li
    Yuanting Gu
    World Journal of Surgical Oncology, 21
  • [39] Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
    You, Shuhui
    Xie, Yizhao
    Sang, Die
    Luo, Ting
    Yuan, Peng
    Xu, Fei
    Wang, Biyun
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [40] Pyrotinib as neoadjuvant therapy for HER2+breast cancer: A multicenter, randomized, controlled, phase II trial.
    Ding, Xiaowen
    Mo, Wenju
    Xie, Xiaohong
    Wang, Ouchen
    Ding, Yuqin
    Zhao, Shuai
    He, Xiangming
    Feng, Weiliang
    Zou, Dehong
    Yang, Hongjian
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345